AU4156197A - Oligonucleotide prodrugs - Google Patents

Oligonucleotide prodrugs

Info

Publication number
AU4156197A
AU4156197A AU41561/97A AU4156197A AU4156197A AU 4156197 A AU4156197 A AU 4156197A AU 41561/97 A AU41561/97 A AU 41561/97A AU 4156197 A AU4156197 A AU 4156197A AU 4156197 A AU4156197 A AU 4156197A
Authority
AU
Australia
Prior art keywords
oligonucleotide prodrugs
prodrugs
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41561/97A
Inventor
Sudhir Agrawal
Theresa Devlin
Radhakrishnan P Iyer
Dong Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of AU4156197A publication Critical patent/AU4156197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
AU41561/97A 1996-08-21 1997-08-21 Oligonucleotide prodrugs Abandoned AU4156197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2426296P 1996-08-21 1996-08-21
US60024262 1996-08-21
PCT/US1997/014751 WO1998007734A1 (en) 1996-08-21 1997-08-21 Oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
AU4156197A true AU4156197A (en) 1998-03-06

Family

ID=21819691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41561/97A Abandoned AU4156197A (en) 1996-08-21 1997-08-21 Oligonucleotide prodrugs

Country Status (2)

Country Link
AU (1) AU4156197A (en)
WO (1) WO1998007734A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1432022A (en) 2000-04-19 2003-07-23 先灵公司 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03005219A (en) 2000-12-12 2003-09-25 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus.
AU2003218630A1 (en) * 2002-03-15 2003-09-29 Nuevolution A/S A building block capable of functional entity transfer to nucleophil
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009146123A2 (en) 2008-04-03 2009-12-03 Spring Bank Compositions and methods for treating viral infections
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CA2747999A1 (en) * 2008-12-23 2010-07-01 Girindus America, Inc. Sulfurizing reagents and their use for oligonucleotides synthesis
BR112012000828A8 (en) 2009-07-06 2017-10-10 Ontorii Inc NEW NUCLEIC ACID PRO-DRUGS AND METHODS OF THEIR USE
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
RU2014105311A (en) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. METHODS FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
MX356830B (en) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Chiral nucleic acid adjuvant.
JP6268157B2 (en) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan Asymmetric auxiliary group
JP2015529073A (en) * 2012-08-20 2015-10-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Polynucleotide having bioreversible group
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547569A (en) * 1982-11-24 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Intercalating agents specifying nucleotides
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA2140542A1 (en) * 1992-07-27 1994-02-03 Abeysingle Padmapriya Oligonucleotide alkylphosphonothioates
FR2705099B1 (en) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Phosphorothioate triester oligonucleotides and process for their preparation.
WO1996007392A2 (en) * 1994-09-07 1996-03-14 Hybridon, Inc. Oligonucleotide prodrugs
WO1996029337A1 (en) * 1995-03-23 1996-09-26 Hybridon, Inc. Thiono triester modified antisense oligodeoxynucleotide phosphorothioates

Also Published As

Publication number Publication date
WO1998007734A1 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
AU2360195A (en) Oligonucleotide repeat arrays
AU1623299A (en) Nucleotide-based prodrugs
AU4040197A (en) Microturbomachinery
AU3387997A (en) Autonotification
AU2845197A (en) Cycloalkano-pyridines
AU4156197A (en) Oligonucleotide prodrugs
AU4013397A (en) Arylalkanoylpyridazines
AU4176997A (en) 3-alkyl-3-phenyl-piperidines
AU2684197A (en) Handleset
AU5259498A (en) Antisense oligonucleotides
AU4218597A (en) Superseat
AU3340797A (en) Modified oligonucleotides
AU2786295A (en) Spacing member
AU7918398A (en) Oligonucleotide derivatives
AU2090897A (en) Hydroxyhexahydropyridazines
AU5697699A (en) Oligonucleotide protecting groups
AU1907095A (en) Spacing member
AU3130597A (en) Tristetraprolin
AU5310500A (en) Pseudomycin prodrugs
AU3782797A (en) Printer
AU1900097A (en) Cremators
AU4332497A (en) Endo-beta-galactosidase
AU2237197A (en) Fishing-lure
AUPO894297A0 (en) A distribution system
AU1597197A (en) Thienoquinolines